- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech High Insider Buying
Hong Kong Pharmaceuticals & Biotech High Insider Buying
Results
10
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
10 companies
Sino Biopharmaceutical
Market Cap: HK$96.9b
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
1177
HK$5.43
7D
0.2%
1Y
38.9%
CSPC Pharmaceutical Group
Market Cap: HK$93.8b
An investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally.
1093
HK$8.20
7D
-2.5%
1Y
42.9%
Shanghai Junshi Biosciences
Market Cap: HK$41.1b
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.
1877
HK$24.48
7D
-7.0%
1Y
65.4%
Grand Pharmaceutical Group
Market Cap: HK$21.5b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
512
HK$6.15
7D
-1.1%
1Y
-17.7%
Everest Medicines
Market Cap: HK$11.5b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$32.82
7D
-5.0%
1Y
-32.0%
CF PharmTech
Market Cap: HK$9.0b
Engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China.
2652
HK$21.90
7D
-1.4%
1Y
n/a
Antengene
Market Cap: HK$3.3b
A clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally.
6996
HK$4.88
7D
-3.0%
1Y
68.9%
Kintor Pharmaceutical
Market Cap: HK$1.4b
A clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China.
9939
HK$2.92
7D
2.8%
1Y
131.7%
Sirnaomics
Market Cap: HK$666.5m
An RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs.
2257
HK$6.12
7D
-4.4%
1Y
100.7%
China NT Pharma Group
Market Cap: HK$597.9m
An investment holding company, engages in the investment, research and development, manufacture, sale, and distribution of pharmaceutical products in the People’s Republic of China.
1011
HK$0.63
7D
-3.1%
1Y
85.3%